

# Mark N Gaze

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6388601/publications.pdf>

Version: 2024-02-01

91  
papers

2,907  
citations

257101

24  
h-index

189595

50  
g-index

91  
all docs

91  
docs citations

91  
times ranked

3186  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pain relief and quality of life following radiotherapy for bone metastases: a randomised trial of two fractionation schedules. <i>Radiotherapy and Oncology</i> , 1997, 45, 109-116.	0.3	263
2	Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 500-514.	5.1	256
3	Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1617-1629.	5.1	252
4	<sup>177</sup> Lu-DOTATATE Molecular Radiotherapy for Childhood Neuroblastoma. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1041-1047.	2.8	144
5	Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG) Tj ETQq1 1 0.784314 rgBT /Overfoc 19, 1061-1071.	5.1	137
6	Feasibility of Dosimetry-Based High-Dose <sup>131</sup> I-Meta-Iodobenzylguanidine with Topotecan as a Radiosensitizer in Children with Metastatic Neuroblastoma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2005, 20, 195-199.	0.7	132
7	A systematic review of <sup>131</sup> I-meta iodobenzylguanidine molecular radiotherapy for neuroblastoma. <i>European Journal of Cancer</i> , 2014, 50, 801-815.	1.3	132
8	<sup>18</sup> F-FDG PET/CT and <sup>123</sup> I-Metaiodobenzylguanidine Imaging in High-Risk Neuroblastoma: Diagnostic Comparison and Survival Analysis. <i>Journal of Nuclear Medicine</i> , 2011, 52, 519-525.	2.8	91
9	Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1). <i>Cancers</i> , 2020, 12, 309.	1.7	84
10	Controversies in the management of laryngeal cancer: results of an international survey of patterns of care. <i>Radiotherapy and Oncology</i> , 1994, 31, 23-32.	0.3	74
11	How rapid advances in imaging are defining the future of precision radiation oncology. <i>British Journal of Cancer</i> , 2019, 120, 779-790.	2.9	69
12	[ <sup>131</sup> I]meta-Iodobenzylguanidine and Topotecan Combination Treatment of Tumors Expressing the Noradrenaline Transporter. <i>Clinical Cancer Research</i> , 2005, 11, 7929-7937.	3.2	61
13	Influence of Surgical Excision on the Survival of Patients With Stage 4 High-Risk Neuroblastoma: A Report From the HR-NBL1/SIOPEN Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 2902-2915.	0.8	60
14	Dosimetry for Fractionated <sup>131</sup> I-mIBG Therapies in Patients with Primary Resistant High-Risk Neuroblastoma: Preliminary Results. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2007, 22, 105-112.	0.7	53
15	Incidence of cavernoma development in children after radiotherapy for brain tumors. <i>Journal of Neurosurgery: Pediatrics</i> , 2007, 106, 379-383.	0.8	52
16	Congenital alveolar rhabdomyosarcomam. <i>Cancer</i> , 2001, 91, 606-612.	2.0	49
17	An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma. <i>BMC Cancer</i> , 2016, 16, 621.	1.1	48
18	Adverse events of local treatment in long-term head and neck rhabdomyosarcoma survivors after external beam radiotherapy or AMORE treatment. <i>European Journal of Cancer</i> , 2015, 51, 1424-1434.	1.3	41

#	ARTICLE	IF	CITATIONS
19	18F-Fluoroethylcholine (18F-Cho) PET/MRI Functional Parameters in Pediatric Astrocytic Brain Tumors. <i>Clinical Nuclear Medicine</i> , 2015, 40, e40-e45.	0.7	41
20	Outcome and prognostic factors in pediatric malignant peripheral nerve sheath tumors: An analysis of the European Pediatric Soft Tissue Sarcoma Group (EpSSG) NRSTSâ€”2005 prospective study. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27833.	0.8	40
21	A new technique of laparoscopic ovariopexy before irradiation. <i>Fertility and Sterility</i> , 2003, 79, 1204-1206.	0.5	32
22	Local therapy is critical in localised pelvic rhabdomyosarcoma: Experience of the International Society of Pediatric Oncology Malignant Mesenchymal Tumor (SIOP-MMT) committee. <i>European Journal of Cancer</i> , 2012, 48, 2020-2027.	1.3	31
23	Results of a Quality Assurance Review of External Beam Radiation Therapy in the International Society of Paediatric Oncology (Europe) Neuroblastoma Group's High-risk Neuroblastoma Trial: A SIOPEN Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 170-174.	0.4	30
24	[131I]MIBG and topotecan: A rationale for combination therapy for neuroblastoma. <i>Cancer Letters</i> , 2005, 228, 221-227.	3.2	26
25	Prognostic relevance of early radiologic response to induction chemotherapy in pediatric rhabdomyosarcoma: A report from the International Society of Pediatric Oncology Malignant Mesenchymal Tumor 95 study. <i>Cancer</i> , 2018, 124, 1016-1024.	2.0	25
26	A phase IIa trial of molecular radiotherapy with 177-lutetium DOTATATE in children with primary refractory or relapsed high-risk neuroblastoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2348-2357.	3.3	23
27	Inhibition of Poly(ADP-Ribose) Polymerase Enhances the Toxicity of <sup>131</sup> I-Metaiodobenzylguanidine/Topotecan Combination Therapy to Cells and Xenografts That Express the Noradrenaline Transporter. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1146-1154.	2.8	22
28	Ten challenges in the management of neuroblastoma. <i>Future Oncology</i> , 2012, 8, 839-858.	1.1	22
29	The UK Experience of a Treatment Strategy for Pediatric Metastatic Medulloblastoma Comprising Intensive Induction Chemotherapy, Hyperfractionated Accelerated Radiotherapy and Response Directed High Dose Myeloablative Chemotherapy or Maintenance Chemothera. <i>Pediatric Blood and Cancer</i> , 2015, 62, 2132-2139.	0.8	21
30	Non-parameningeal head and neck rhabdomyosarcoma in children, adolescents, and young adults: Experience of the European paediatric Soft tissue sarcoma Study Group (EpSSG) â€” RMS2005 study. <i>European Journal of Cancer</i> , 2021, 151, 84-93.	1.3	21
31	68Ga-DOTATATE and 123I-mIBG as imaging biomarkers of disease localisation in metastatic neuroblastoma: implications for molecular radiotherapy. <i>Nuclear Medicine Communications</i> , 2020, 41, 1169-1177.	0.5	21
32	Radiation exposure to comforters and carers during paediatric molecular radiotherapy. <i>Pediatric Blood and Cancer</i> , 2015, 62, 235-239.	0.8	19
33	Paratesticular rhabdomyosarcoma in children and adolescentsâ€”Outcome and patterns of relapse when utilizing a nonsurgical strategy for lymph node staging: Report from the International Society of Paediatric Oncology (SIOP) Malignant Mesenchymal Tumour 89 and 95 studies. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26486.	0.8	19
34	The Evidence for External Beam Radiotherapy in High-Risk Neuroblastoma of Childhood: A Systematic Review. <i>Clinical Oncology</i> , 2019, 31, 182-190.	0.6	18
35	Outcomes of metastatic non-rhabdomyosarcoma soft tissue sarcomas (NRSTS) treated within the BERNIE study: a randomised, phase II study evaluating the addition of bevacizumab to chemotherapy. <i>European Journal of Cancer</i> , 2020, 130, 72-80.	1.3	18
36	The current status of targeted radiotherapy in clinical practice. <i>Physics in Medicine and Biology</i> , 1996, 41, 1895-1903.	1.6	17

#	ARTICLE	IF	CITATIONS
37	Successful treatment of MYCN amplified, progressive stage 4S neuroblastoma in a neonate with hepatic artery embolization in addition to multimodality treatment. <i>Pediatric Blood and Cancer</i> , 2006, 46, 253-257.	0.8	17
38	Intensity-modulated arc therapy to improve radiation dose delivery in the treatment of abdominal neuroblastoma. <i>Future Oncology</i> , 2013, 9, 439-449.	1.1	16
39	Local staging and treatment in extremity rhabdomyosarcoma. A report from the EpSSGâ€RMS2005 study. <i>Cancer Medicine</i> , 2020, 9, 7580-7589.	1.3	16
40	Phaeochromocytomas and Paragangliomas: A difference in disease behaviour and clinical outcomes. <i>Journal of Surgical Oncology</i> , 2015, 112, 486-491.	0.8	15
41	The Impact of Radiation Therapy in Children and Adolescents With Metastatic Rhabdomyosarcoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 968-978.	0.4	15
42	QUARTET: A SIOP Europe project for quality and excellence in radiotherapy and imaging for children and adolescents with cancer. <i>European Journal of Cancer</i> , 2022, 172, 209-220.	1.3	15
43	Current Management of Neuroblastoma. <i>Oncologist</i> , 1998, 3, 253-262.	1.9	14
44	Medulloblastoma as a First Presentation of Fanconi Anemia. <i>Journal of Pediatric Hematology/Oncology</i> , 2004, 26, 52-55.	0.3	14
45	MRI-guided radiotherapy of the SK-N-SH neuroblastoma xenograft model using a small animal radiation research platform. <i>British Journal of Radiology</i> , 2017, 90, 20160427.	1.0	14
46	Differentiated Thyroid Cancer in Children: A UK Multicentre Review and Review of the Literature. <i>Clinical Oncology</i> , 2019, 31, 385-390.	0.6	14
47	Calcified cerebral metastasis from cervical carcinoma. <i>Neuroradiology</i> , 1989, 31, 291-291.	1.1	13
48	Immunohistochemical evaluation of molecular radiotherapy target expression in neuroblastoma tissue. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 402-411.	3.3	13
49	The spleen as an organ at risk in paediatric radiotherapy: A SIOP-Europe Radiation Oncology Working Group report. <i>European Journal of Cancer</i> , 2021, 143, 1-10.	1.3	13
50	Hypertension complicating <sup>131</sup> I-meta-iodobenzylguanidine therapy for neuroblastoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 597-601.	3.3	12
51	Radiotherapy practice for paediatric brain tumours across Europe and quality assurance initiatives: Current situation, international survey and future perspectives. <i>European Journal of Cancer</i> , 2019, 114, 36-46.	1.3	12
52	Psychosocial well-being of long-term survivors of pediatric head&neck rhabdomyosarcoma. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27498.	0.8	12
53	An evaluation <i>in vitro</i> of the efficacy of nutlin-3 and topotecan in combination with <sup>177</sup> Lu-DOTATATE for the treatment of neuroblastoma. <i>Oncotarget</i> , 2018, 9, 29082-29096.	0.8	12
54	Development of an electronic database for quality assurance of radiotherapy in the International Society of Paediatric Oncology (Europe) high risk neuroblastoma study. <i>Radiotherapy and Oncology</i> , 2010, 97, 593-595.	0.3	11

#	ARTICLE	IF	CITATIONS
55	Successful treatment of central nervous system PTLD with rituximab and cranial radiotherapy. <i>Pediatric Nephrology</i> , 2013, 28, 2053-2056.	0.9	11
56	Evaluation of treatment response using integrated <sup>18</sup> F- $\alpha$ -labeled choline positron emission tomography/magnetic resonance imaging in adolescents with intracranial non-germinomatous germ cell tumours. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1661-1663.	0.8	11
57	Improved outcome of <sup>131</sup> I-mIBG treatment through combination with external beam radiotherapy in the SK-N-SH mouse model of neuroblastoma. <i>Radiotherapy and Oncology</i> , 2017, 124, 488-495.	0.3	11
58	Outcome of localized liver bile duct rhabdomyosarcoma according to local therapy: A report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG) RMS 2005 study. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27725.	0.8	11
59	Treating papillary and follicular thyroid cancer in children and young people: Single UK-center experience between 2003 and 2018. <i>Journal of Pediatric Surgery</i> , 2021, 56, 534-539.	0.8	11
60	Inhibition of glycolysis and mitochondrial respiration promotes radiosensitisation of neuroblastoma and glioma cells. <i>Cancer &amp; Metabolism</i> , 2021, 9, 24.	2.4	11
61	Differential intracellular processing of the anthracycline drug ME2303 in doxorubicin-sensitive (A2780) and -resistant (A2780AD) human ovarian cancer cells as studied with confocal laser scanning microscopy and image analysis. <i>International Journal of Cancer</i> , 1994, 59, 94-102.	2.3	10
62	<scp>MRI</scp> abnormalities in children following sequential chemotherapy, hyperfractionated accelerated radiotherapy and high-dose thiotepa for high-risk primitive neuroectodermal tumours of the central nervous system. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2014, 58, 683-690.	0.9	10
63	Pencil Beam Scanning Proton Therapy Case Selection for Paediatric Abdominal Neuroblastoma: Effects of Tumour Location and Bowel Gas. <i>Clinical Oncology</i> , 2021, 33, e132-e142.	0.6	9
64	Treatment outcome with a selective RET tyrosine kinase inhibitor selipratinib in children with multiple endocrine neoplasia type 2 and advanced medullary thyroid carcinoma. <i>European Journal of Cancer</i> , 2021, 158, 38-46.	1.3	9
65	The nature of the head and neck cancer. <i>European Archives of Oto-Rhino-Laryngology</i> , 1993, 250, 127-32.	0.8	8
66	Conservative or radical surgery for pediatric papillary thyroid carcinoma: A systematic review of the literature. <i>International Journal of Pediatric Otorhinolaryngology</i> , 2015, 79, 1620-1624.	0.4	8
67	Parents' responses to prognostic disclosure at diagnosis of a child with a high-risk brain tumor: Analysis of clinician-parent interactions and implications for clinical practice. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28802.	0.8	8
68	Localised rhabdomyosarcoma in infants (<math>\leq 12</math> months) and young children (12-36 months of age) treated on the EpSSG RMS 2005 study. <i>European Journal of Cancer</i> , 2022, 160, 206-214.	1.3	8
69	Paediatric differentiated thyroid carcinoma: a UK National Clinical Practice Consensus Guideline. <i>Endocrine-Related Cancer</i> , 2022, , .	1.6	8
70	Personalisation of Molecular Radiotherapy through Optimisation of Theragnostics. <i>Journal of Personalized Medicine</i> , 2020, 10, 174.	1.1	6
71	Atlas construction and spatial normalisation to facilitate radiation-induced late effects research in childhood cancer. <i>Physics in Medicine and Biology</i> , 2021, 66, 105005.	1.6	6
72	Bladder function after conservative surgery and high-dose rate brachytherapy for bladder-prostate rhabdomyosarcoma. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29574.	0.8	6

#	ARTICLE	IF	CITATIONS
73	Optimum combination of targeted <sup>131</sup> I and total body irradiation for treatment of disseminated cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 1995, 32, 713-721.	0.4	5
74	Impact of induction chemotherapy, hyperfractionated accelerated radiotherapy and high-dose thiotepa on brain volume loss and functional status of children with primitive neuroectodermal tumour. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26619.	0.8	5
75	Radical radiotherapy for paediatric solid tumour metastases: An overview of current European protocols and outcomes of a SIOPE multicenter survey. <i>European Journal of Cancer</i> , 2021, 145, 121-131.	1.3	5
76	Assessment of the impact of CT calibration procedures for proton therapy planning on pediatric treatments. <i>Medical Physics</i> , 2021, 48, 5202-5218.	1.6	5
77	Risk of radiation-induced second malignant neoplasms from photon and proton radiotherapy in paediatric abdominal neuroblastoma. <i>Physics and Imaging in Radiation Oncology</i> , 2021, 19, 45-52.	1.2	5
78	A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of <sup>177</sup> Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastoma—LuDO-N. <i>Frontiers in Pediatrics</i> , 2022, 10, 836230.	0.9	5
79	Opportunities for research in molecular radiotherapy. <i>British Journal of Radiology</i> , 2017, 90, 20160921.	1.0	4
80	Current experience with mIBG therapy in combination with chemotherapy and radiosensitizers. <i>Nuclear Medicine and Biology</i> , 2008, 35, S21-S26.	0.3	3
81	<sup>68</sup> Ga-DOTATATE uptake in pineal gland, a rare physiological variant: case series. <i>Annals of Nuclear Medicine</i> , 2015, 29, 833-837.	1.2	3
82	Renal protection during <sup>177</sup> lutetium DOTATATE molecular radiotherapy in children: a proposal for safe amino acid infusional volume during peptide receptor radionuclide therapy. <i>Nuclear Medicine Communications</i> , 2022, 43, 242-246.	0.5	3
83	Semi-quantitative scoring of skeletal metastases by <sup>123</sup> I-mIBG scintigraphy in high-risk neuroblastoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1251-1253.	3.3	2
84	Childhood medulloblastoma—a single institution's historical perspective on survival and functional morbidity. <i>Child's Nervous System</i> , 2019, 35, 2327-2338.	0.6	2
85	European clinical trials in paediatric radiation oncology. <i>The Lancet Child and Adolescent Health</i> , 2021, 5, 843-845.	2.7	2
86	Impact of cyclic changes in pharmacokinetics and absorbed dose in pediatric neuroblastoma patients receiving [ <sup>177</sup> Lu]Lu-DOTATATE. <i>EJNMMI Physics</i> , 2022, 9, 24.	1.3	2
87	Current Issues in Molecular Radiotherapy in Children. , 2016, , 29-49.		1
88	Contemporary paediatric radiation oncology. <i>Archives of Disease in Childhood</i> , 2023, 108, 332-337.	1.0	1
89	Imaging in Pediatric Oncology: New Advances and Techniques. <i>Pediatric Oncology</i> , 2019, , 1-7.	0.5	0
90	Patient-reported Late Effects of Single Fraction Total Body Irradiation for Non-malignant Haematological Disease Transplant Conditioning. <i>Clinical Oncology</i> , 2022, , .	0.6	0

#	ARTICLE	IF	CITATIONS
91	RONC-01. A 10 year, single institution experience of re-irradiation for paediatric intracranial tumours. Neuro-Oncology, 2022, 24, i176-i176.	0.6	0